FDA approves Sun’s sale of benzonatate
MUMBAI, India The Food and Drug Administration has recently approved the selling of benzonatate capsules, manufactured by India-based Sun Pharmaceutical Industries.
According to published reports, the benzonatate capsules, which are used to treat cough, common cold and pneumonia, as well as other lung infections, are the generic version of Forest Labs’ Tessalon.
The drug will be sold in 100 mg and 200 mg doses. Sun will start selling the drug very soon, adding sales to its already $40 million per year revenue in the U.S.
Canada court blocks sale of generic form of Lipitor
NEW YORK Canada’s appeals court ruled in favor of Pfizer not allowing Ranbaxy Labs to produce the generic version of the drug Lipitor, according to published reports.
The decision overturned a ruling made by lower courts that stated that the patent could not prohibit Ranbaxy from selling a cheaper version of Lipitor (atorvastin calcium), which is used to fight cholesterol.
The appeals court of Canada decided that Ranbaxy could manufacture its product as soon as Pfizer’s product expires in 2010, which leads many to believe that this decision will push Ranbaxy to take the matter to the Supreme Court of Canada.
McCain’s healthcare plan suggests a loss for pharmaceutical companies
WASHINGTON John McCain’s healthcare plan, with a call to purchase drugs in Canada, may cost American pharmaceutical companies billions of dollars, according to published reports.
According to McCain, the Republican presidential candidate, “The problem is not that most Americans lack adequate health insurance, the biggest problem with the American healthcare system is that it costs too much.”
McCain’s health policy would allow citizens to purchase medicines legally from Canada, which would make them more affordable for the reported 47 million Americans that don’t have health coverage.
According to published reports, such drugs as Pfizer’s Lipitor, known as the world’s biggest selling drug, costs $60.78 for a 30-day supply of 20 mg pills on CanadaDrugs.com, whereas Drugstore.com in the U.S. sells the same pill in the same amount for $119.99.
The new policy is predicted to cost drug makers—like Pfizer—about $40 billion over 10 years, according to a report by the Congressional Budget Office.